Group 1 - The core viewpoint of the articles highlights the financial performance and growth potential of Crown BioMed-A (APLM), showcasing a significant increase in revenue and net profit [1][2]. - As of December 31, 2023, Crown BioMed-A reported total revenue of $71.604 million, representing a year-over-year growth of 62.06% [1]. - The company recorded a net profit attributable to shareholders of $172.6 million, which is a 28.33% increase compared to the previous year [2]. Group 2 - Crown BioMed Limited is an innovative biotechnology company focused on exploring and developing cancer therapies that may combine with other treatment options, utilizing the immune system and targeting specific molecular signaling pathways to inhibit cancer [2]. - The company operates in both the United States and China, believing it has favorable conditions to leverage collaborations with other biotechnology firms in the East and West [2]. - Since its establishment in 2015, under the leadership of an experienced management team, the company has developed a pipeline consisting of ten oncology-focused drug candidates across twelve projects, with five candidates currently in clinical stages [2].

Core Viewpoint - Kelun Pharmaceutical has significant ownership in Kelun Biotech and is actively developing a diverse pipeline of innovative drugs targeting various diseases [2] Company Summary - As of June 30, 2025, Kelun Pharmaceutical directly holds 51.45% of Kelun Biotech and indirectly holds 4.97% [2] - Kelun Biotech has over 30 innovative drug candidates in its research pipeline, focusing on oncology and non-oncology diseases such as autoimmune and metabolic disorders [2]